Replies to post #160940 on Biotech Values

[DewDiligence]

XOMA—I consider the additional data in Behçet’s to be largely a non-event given how striking the early results (and thus the massive overpowering of the Behçet’s ph3).

Respectfully disagree; I thought the new data on Servier’s follow-up phase-2 in Behçet’s was the most consequential revelation on the CC because of the granularity on the vitreous-haze endpoint.

In the phase-2 Behçet’s study, a 2-step reduction in vitreous haze (the primary endpoint in EYEGUARD-B) was seen in several patients on the 30mg dose as well as the 60mg dose, which is the dose being used in EYEGUARD-B. Since the 30mg dose apparently has good efficacy, the fact that Servier decided to go with solely the 60mg dose in phase-3 suggests that safety is not as big a concern in this indication as you might think.